Evidence
Cell Mol Life Sci. 2024 Apr 23;81(1):192. doi: 10.1007/s00018-024-05225-z.
ABSTRACT
BACKGROUND: Alzheimer’s disease (AD) is pathologically characterized by the abnormal accumulation of Aβ and tau proteins. There has long been a keen interest among researchers in understanding how Aβ and tau are ultimately cleared in the brain. The discovery of this glymphatic system introduced a novel perspective on protein clearance and it gained recognition as one of the major brain clearance pathways for clearing these pathogenic proteins in AD. This finding has sparked interest in exploring the potential contribution of the glymphatic/meningeal lymphatic system in AD. Furthermore, there is a growing emphasis and discussion regarding the possibility that activating the glymphatic/meningeal lymphatic system could serve as a novel therapeutic strategy against AD.
OBJECTIVES: Given this current research trend, the primary focus of this comprehensive review is to highlight the role of the glymphatic/meningeal lymphatic system in the pathogenesis of AD. The discussion will encompass future research directions and prospects for treatment in relation to the glymphatic/meningeal lymphatic system.
PMID:38652179 | DOI:10.1007/s00018-024-05225-z
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Involvement of the glymphatic/meningeal lymphatic system in Alzheimer’s disease: insights into proteostasis and future directions
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Glymphatic dysfunction as a driver of Alzheimer’s disease: Moving past the hype
- Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease
- Tau fibrils evade autophagy by excessive p62 coating and TAX1BP1 exclusion
- Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study
- Is cerebral small vessel disease a central nervous system interstitial fluidopathy?
- The duality of amyloid-β: its role in normal and Alzheimer's disease states
- CSF formation rate-a potential glymphatic flow parameter in hydrocephalus?
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- Tau follows principal axes of functional and structural brain organization in Alzheimer's disease
- Glymphatic system dysfunction in mood disorders: Evaluation by diffusion magnetic resonance imaging
- Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease
- Search for unknown neural link between the masticatory and cognitive brain systems to clarify the involvement of its impairment in the pathogenesis of Alzheimer's disease
- Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging
- A Review of the Role of Estrogens in Olfaction, Sleep and Glymphatic Functionality in Relation to Sex Disparity in Alzheimer's Disease
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- S100 proteins: a new frontier in fibromyalgia research
- Association study of brain structure-function coupling and glymphatic system function in patients with mild cognitive impairment due to Alzheimer's disease
- Neuroimmune Dysfunction in Alzheimer's Disease and Other Forms of Dementia
- Early and selective localization of tau filaments to glutamatergic subcellular domains within the human anterodorsal thalamus
- Towards cascading genetic risk in Alzheimer's disease
- Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China
- A clathrin mediated endocytosis scaffolding protein, Intersectin 1, changes in an isoform, brain region, and sex specific manner in Alzheimer's disease
- Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
- Apolipoprotein E2 Expression Alters Endosomal Pathways in a Mouse Model With Increased Brain Exosome Levels During Aging
- G272V and P301L mutations induce isoform specific tau mislocalization to dendritic spines and synaptic dysfunctions in cellular models of 3R and 4R tau frontotemporal dementia
- Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry
- Research progress on astrocyte-derived extracellular vesicles in the pathogenesis and treatment of neurodegenerative diseases
- Cholecystokinin neurotransmission in the central nervous system: Insights into its role in health and disease
- Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid
- In situ seeding assay: A novel technique for direct tissue localization of bioactive tau
- Tau protein profiling in tauopathies: a human brain study
- The influence of APOEε4 on the pTau interactome in sporadic Alzheimer's disease
- Differential Cytokine Responses of APOE3 and APOE4 Blood-brain Barrier Cell Types to SARS-CoV-2 Spike Proteins
- Ubiquitin system mutations in neurological diseases
- Cannabidiol and Neurodegeneration: From Molecular Mechanisms to Clinical Benefits
- Cannabidiol and Neurodegeneration: From Molecular Mechanisms to Clinical Benefits
- Neuronal double-stranded DNA accumulation induced by DNase II deficiency drives tau phosphorylation and neurodegeneration
- Astrocyte tau deposition in progressive supranuclear palsy is associated with dysregulation of MAPT transcription
- The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways
- Potassium and calcium channels in different nerve cells act as therapeutic targets in neurological disorders
- Small but mighty: the rise of microprotein biology in neuroscience
- Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer's disease
- Molecular overlaps of neurological manifestations of COVID-19 and schizophrenia from a proteomic perspective
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Rejuvenation of peripheral immune cells attenuates Alzheimer's disease-like pathologies and behavioral deficits in a mouse model
- A new tau dephosphorylation-targeting chimera for the treatment of tauopathies
- P2Y1 receptor in Alzheimer's disease
- Alzheimer-Type Cerebral Amyloidosis in the Context of HIV Infection: Implications for a Proposed New Treatment Approach
- Preclinical efficacy of oral and nasal rivastigmine-loaded chitosan nano-particles on AlCl3-induced Alzheimer's-like disease in rats
- Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studies
- Involvement of the choroid plexus in Alzheimer's disease pathophysiology: findings from mouse and human proteomic studies
- Unraveling the Potential Underlying Mechanisms of Mild Behavioral Impairment: Focusing on Amyloid and Tau Pathology
- 1-Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance
- A methodology to globally assess ectodomain shedding using soluble fractions from the mouse brain
- Phytoactive drugs used in the treatment of Alzheimer's disease and dementia
- Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease
- Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease
- Activation of the Neuronal Cell Cycle in Brains in Amnestic Mild Cognitive Impairment: Early Involvement in the Progression of Alzheimer's Disease
- Improving Cognition Without Clearing Amyloid: Effects of Tau and Ultrasound Neuromodulation
- Alzheimer's disease and sleep disorders: a bidirectional relationship
- Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias
Evidence Blueprint
Involvement of the glymphatic/meningeal lymphatic system in Alzheimer’s disease: insights into proteostasis and future directions
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Involvement of the glymphatic/meningeal lymphatic system in Alzheimer’s disease: insights into proteostasis and future directions
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Interplay between the glymphatic system and neurotoxic proteins in Parkinson's disease and related disorders: current knowledge and future directions
- Glymphatic dysfunction as a driver of Alzheimer’s disease: Moving past the hype
- Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
- Deregulation of the Glymphatic System in Alzheimer's Disease: Genetic and Non-Genetic Factors
- Impaired Meningeal Lymphatics and Glymphatic Pathway in Patients with White Matter Hyperintensity
- Unraveling the lymphatic system in the spinal cord meninges: a critical element in protecting the central nervous system
- Chronic sleep fragmentation impairs brain interstitial clearance in young wildtype mice
- Human brain clearance imaging: Pathways taken by magnetic resonance imaging contrast agents after administration in cerebrospinal fluid and blood
- Global brain activity and its coupling with cerebrospinal fluid flow is related to tau pathology
- Mistranslation-associated perturbations of proteostasis do not promote accumulation of amyloid beta and plaque deposition in aged mouse brain
- Reduced Diffusivity Along Perivascular Spaces on Magnetic Resonance Imaging Associated with Younger Age of First Use and Cognitive Impairment in Recreational Marijuana Users
- Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease
- Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis
- p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003
- BV2 Membrane-coated PEGylated-liposomes Delivered hFGF21 to Cortical and Hippocampal Microglia for Alzheimer's Disease Therapy
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Tau fibrils evade autophagy by excessive p62 coating and TAX1BP1 exclusion
- Unraveling the impact of Omega-3 polyunsaturated fatty acids on blood-brain barrier (BBB) integrity and glymphatic function
- Quantifying the Lymphatic Transport of Model Therapeutics from the Brain in Rats
- Neonatal stress disrupts the glymphatic system development and increases the susceptibility to Parkinson's disease in later life
- Role of Oxidative Stress, Methionine Oxidation and Methionine Sulfoxide Reductases (MSR) in Alzheimer's Disease
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study
- Tau accumulation and its spatial progression across the Alzheimer's disease spectrum
- New insights into the therapeutic approaches for the treatment of tauopathies
- Is cerebral small vessel disease a central nervous system interstitial fluidopathy?
- Chronic kidney disease causes blood-brain barrier breakdown via urea-activated matrix metalloproteinase-2 and insolubility of tau protein
- Biochemical approaches to assess the impact of post-translational modifications on pathogenic tau conformations using recombinant protein
- The duality of amyloid-β: its role in normal and Alzheimer's disease states
- CSF formation rate-a potential glymphatic flow parameter in hydrocephalus?
- Mutant α-synuclein propagates via the lymphatic system of the brain in the monomeric state
- Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance
- Autophagy and exosomes; inter-connected maestros in Alzheimer's disease
- Tau follows principal axes of functional and structural brain organization in Alzheimer's disease
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits
- Exposure to low-intensity blast increases clearance of brain Aβ
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology
- Glymphatic system dysfunction in mood disorders: Evaluation by diffusion magnetic resonance imaging
- Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Impact of Sleep Disorders and Disturbed Sleep on Brain Health: A Scientific Statement From the American Heart Association
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Resting-state fMRI network efficiency as a mediator in the relationship between the glymphatic system and cognitive function in obstructive sleep apnea hypopnea syndrome: Insights from a DTI-ALPS investigation
- Navigating the metabolic maze: anomalies in fatty acid and cholesterol processes in Alzheimer's astrocytes
- Imaging of brain barrier inflammation and brain fluid drainage in human neurological diseases
- Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease
- Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease
- Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells
- Search for unknown neural link between the masticatory and cognitive brain systems to clarify the involvement of its impairment in the pathogenesis of Alzheimer's disease
- Molecular cross-talk between long COVID-19 and Alzheimer's disease
- Tau and Alzheimer's disease: Past, present and future
- Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy
- Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging
- Advancements in investigating the role of cerebral small vein loss in Alzheimer's disease-related pathological changes
- A Review of the Role of Estrogens in Olfaction, Sleep and Glymphatic Functionality in Relation to Sex Disparity in Alzheimer's Disease
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- A microtubule stabilizer ameliorates protein pathogenesis and neurodegeneration in mouse models of repetitive traumatic brain injury
- Investigating neural dysfunction with abnormal protein deposition in Alzheimer's disease through magnetic resonance spectroscopic imaging, plasma biomarkers, and positron emission tomography
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver